High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001853:Bone Marrow / Q000201:enzymology*; D001854:Bone Marrow Cells; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions; D004912:Erythrocytes / Q000201:enzymology*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010088:Oxidoreductases / Q000097:blood* / Q000378:metabolism; D010612:Pharyngitis / Q000139:chemically induced; D011379:Prognosis; D012075:Remission, Spontaneous; D014839:Vomiting / Q000139:chemically induced
D010088:Oxidoreductases; D003630:Daunorubicin